- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07438782
Første gang på mennesker (FTIH) undersøgelse for at undersøge sikkerheden og foreløbig aktivitet af GSK5533524 alene eller i kombination hos voksne deltagere med fremskredne solide tumorer
En fase 1, åben-label, multicenterundersøgelse af GSK5533524 alene eller i kombination med andre antikancerlægemidler hos voksne deltagere med udvalgte fremskredne solide tumorer
The purpose of this study is to investigate a new drug GSK5533524 in adults with certain advanced cancers to find a safe dose and learn how well people tolerate it, so researchers can choose the best dose for the next stage of testing. The study will also check whether the drug can shrink tumours or slow cancer growth, monitor how the body absorbs and breaks down the drug, and look for any immune reactions that the body might develop against the treatment.
Studieoversigt
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Undersøgelse Kontakt Backup
- Navn: EU GSK Clinical Trials Call Center
- Telefonnummer: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Stephanie Lheureux
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- susie lau
-
Montreal, Quebec, Canada, H2X 0A9
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Diane Provencher
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
Capital Region
-
København Ø, Capital Region, Danmark, 2100
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Lise Omland
-
-
-
-
-
Cambridge, Det Forenede Kongerige, CB2 2QQ
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Joo Ern Ang
-
Edinburgh, Det Forenede Kongerige, EH4 2XU
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Charlie Gourley
-
-
-
-
-
Helsinki, Finland, 00029
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Katriina Jalkanen
-
-
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107-4330
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Ida Micaily
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78229-3307
- Rekruttering
- GSK Investigational Site
-
Ledende efterforsker:
- Drew Rasco
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Bordeaux, Frankrig, 33076
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Coriolan Lebreton
-
Villejuif, Frankrig, 94805
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Kaissa Ouali
-
-
-
-
-
Saitama, Japan, 350-1298
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Kosei Hasegawa
-
Shizuoka, Japan, 411-8777
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Akiko Furusawa
-
Tokyo, Japan, 104-0045
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Kan Yonemori
-
Tokyo, Japan, 135-8550
- Rekruttering
- GSK Investigational Site
-
Ledende efterforsker:
- Shigehisa Kitano
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Elena Garralda Cabanas
-
Madrid, Spanien, 28009
- Rekruttering
- GSK Investigational Site
-
Ledende efterforsker:
- Ana Oaknin
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Madrid, Spanien, 28027
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Antonio González Martín
-
Madrid, Spanien, 28041
- Rekruttering
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Ledende efterforsker:
- Ainhoa Madariaga Urrutia
-
Madrid, Spanien, 28050
- Rekruttering
- GSK Investigational Site
-
Ledende efterforsker:
- Emiliano Calvo Aller
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Is at least 18 years of age or the legal age of consent
- Has histologically or cytologically confirmed advanced/metastatic solid tumor that is refractory or intolerant to standard therapy, has exhausted all treatment options and is not considered a candidate for definitive radiotherapy.
- Has documented disease progression based on radiologic imaging, during or after most recent line of treatment.
- Has at least one target lesion per RECIST 1.1.
- Has an Eastern Cooperative Oncology Group performance status of 0 or 1 and no deterioration in the 2 weeks before enrollment.
- Has adequate organ function.
- Has a life expectancy of at least 3 months.
Exclusion Criteria:
- Has a history of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, congestive heart failure or clinically significant arrhythmia not controlled by Standard of care therapy.
- Presence of pleural/abdominal effusion/ascites requiring clinical intervention; presence of pericardial effusion.
- Has untreated brain or central nervous system metastases or metastases that have progressed
- Has a Grade ≥2 corneal epithelial condition.
- Has any active renal condition
- Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening.
- Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy.
- Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or current ILD/pneumonitis.
- Has a lung-specific intercurrent clinically significant illness
- Has FEV1 <50% predicted
- Has chronic enteritis or inflammatory bowel disease or any history of clinically significant bleeding of gastrointestinal tract or clinically significant obstruction and/or perforation and/or fistulae of GI tract.
- Has a known hypersensitivity to any component of GSK5533524 or its excipients.
- Has history of severe allergies, or severe infusion related reactions, or idiosyncrasy to recombinant humanized proteins.
- Has received any cytotoxic chemotherapy drugs, or other anti-tumor drugs within 28 days prior to the first dose of study drug.
- Has received radiotherapy to the lungs, or to adjacent organs, within 6 months prior to the first dose of study intervention; locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study intervention.
- Has received immunosuppressive agents or required long-term glucocorticoid therapy within 30 days prior to first dose of study treatment.
- The use of concomitant medications known to prolong the QT/QTc interval or potentially cause torsades de pointes.
- Has corrected QT interval by Fridericia formula (QTcF) >470 msec or QTcF >480 msec for participants with bundle branch block.
- Has a left ventricular ejection fraction (LVEF) < 50%.
- Has risk factors for prolonged QT/QTc or TdP, such as heart failure, refractory hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of any direct relative under 40 years old.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Del 1b: GSK5533524 Dosisudvidelse
|
GSK5533524 will be administered. |
|
Eksperimentel: Part 1a: GSK5533524 Dose Escalation
|
GSK5533524 will be administered. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Del 1a: Antal deltagere med dosisbegrænsende toksiciteter (DLTs) pr. dosisniveau
Tidsramme: Op til 21 dage
|
Op til 21 dage
|
|
|
Del 1a: Antal deltagere med bivirkninger (AEs), alvorlige bivirkninger (SAEs), efter sværhedsgrad pr. dosisniveau
Tidsramme: Op til cirka 34 måneder
|
Op til cirka 34 måneder
|
|
|
Part 1b: Objective Response Rate (ORR)
Tidsramme: Up to approximately 27 months
|
ORR is defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). |
Up to approximately 27 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Del 1a & 1b: Antal deltagere med bivirkninger (AEs), alvorlige bivirkninger (SAEs), behandlingsrelaterede bivirkninger (TEAEs) efter sværhedsgrad, særligt interesserende bivirkninger (AESIs) og bivirkninger, der fører til dosisændringer og behandlingsafbrydelse
Tidsramme: Op til cirka 34 måneder
|
Op til cirka 34 måneder
|
|
|
Del 1a & 1b: Farmakokinetiske (PK) koncentrationer af GSK5533524 og dets komponenter
Tidsramme: Op til cirka 27 måneder
|
Op til cirka 27 måneder
|
|
|
Del 1a & 1b: Antal deltagere med anti-lægemiddel-antistoffer (ADA) mod GSK5533524
Tidsramme: Op til cirka 27 måneder
|
Op til cirka 27 måneder
|
|
|
Del 1a & 1b: Titre af ADA mod GSK5533524
Tidsramme: Op til cirka 27 måneder
|
Op til cirka 27 måneder
|
|
|
Part 1a: Objective Response Rate (ORR)
Tidsramme: Up to approximately 27 months
|
ORR is the proportion of participants with a BOR of CR or PR as assessed by the investigator according to RECIST 1.1. |
Up to approximately 27 months
|
|
Part 1a & 1b: Duration of Response (DoR)
Tidsramme: Up to approximately 27 months
|
DoR is evaluated in participants who achieve a CR or PR, based on investigator assessment per RECIST 1.1. |
Up to approximately 27 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 300163
- 2025-524165-25 (Anden identifikator: EU CT Number)
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD-delingstidsramme
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD-delingsadgangskriterier
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .